Brouwinkind Pharmalab Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.50 Cr
- Revenue Growth %
- Profit Growth -30.88%
- Ebitda -33.79%
- Net Worth -6.49%
- Total Assets -7.00%
About Brouwinkind Pharmalab
Brouwinkind Pharmalab Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 September 2008 and has a history of 16 years and four months. Its registered office is in Delhi, India.
The Corporate was formerly known as Burroughs Wellcome Pharmalab Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.50 Cr.
August Thirani and Parkash Thirani serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33110DL2008PTC183320
-
Company No.
183320
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Sep 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Brouwinkind Pharmalab?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
August Thirani
|
Director | 09-Jul-2009 | Current |
|
Parkash Thirani
|
Director | 09-Jul-2009 | Current |
Financial Performance of Brouwinkind Pharmalab.
Brouwinkind Pharmalab Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 30.88% decrease in profit. The company's net worth dipped by a decrease of 6.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brouwinkind Pharmalab?
In 2019, Brouwinkind Pharmalab had a promoter holding of 17.50% and a public holding of 82.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹35.00 M
₹0
Charges Breakdown by Lending Institutions
- Uco Bank : 3.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Aug 2009 | Uco Bank | ₹3.50 Cr | Open |
How Many Employees Work at Brouwinkind Pharmalab?
Unlock and access historical data on people associated with Brouwinkind Pharmalab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brouwinkind Pharmalab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brouwinkind Pharmalab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
